![]() | |
![]() | |
Names | |
---|---|
IUPAC name 1,1-Dimethylpiperidinium-4-yl octadecyl phosphate | |
Other names D 21266; KRX 0401 | |
Identifiers | |
3D model (JSmol) | |
ChEMBL | |
ChemSpider | |
ECHA InfoCard | 100.217.789 |
PubChem CID | |
UNII | |
CompTox Dashboard (EPA) | |
| |
| |
Properties | |
C25H52NO4P | |
Molar mass | 461.668 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). |
Perifosine (also KRX-0401) is a former drug candidate that was under development for a variety of cancer indications. It is an alkyl-phospholipid [1] structurally related to miltefosine. Perifosine interrupts the PI3K/AKT/mTOR pathway by acting as an allosteric AKT inhibitor targeting the pleckstrin homology domain of AKT. [2] It was being developed by Keryx Biopharmaceuticals who had licensed it from Æterna Zentaris Inc. [3]
In 2010, perifosine received orphan drug status in the U.S. for the treatment of multiple myeloma and neuroblastoma, and for multiple myeloma in the EU. [4] However, both were later withdrawn. [5] [6]
In 2011 it was in a phase III trial for colorectal cancer, [7] and another for multiple myeloma. [4] [8] On April 2, 2012, it was announced that perifosine failed its phase III clinical trial for treatment of colon cancer. [9] Detailed results were released in June 2012. [10] On March 11, 2013 Aeterna Zentaris announced the discontinuing of Phase 3 clinical trial of perifosine for the treatment of relapsed and refractory multiple myeloma. [11]